Data demonstrate a low major adverse event rate of 0.95% through 30 days post-procedure TEL AVIV, Israel and MIAMI, Nov. 01, 2023 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today presented 30-day results from the C-GUARDIANS […]
Other News
Using iPS Cells from I Peace, Heartseed Succeeds in Stable Production of High Purity Cardiomyocytes, A Major Step Forward in Advancing Autologous Cardiac Regenerative Medicine
PALO ALTO, Calif., Nov. 1, 2023 /PRNewswire/ — Leading GMP cell CDMO I Peace, Inc. (https://www.ipeace.com), specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies based in Palo Alto, CA, and Heartseed Inc. (“Heartseed”), a Tokyo-based biotechnology…
Covera Health Announces Up to $50M in Additional Series C Funding to Redefine the Role of Radiology Nationwide
Company Expands Industry’s Most Sophisticated AI-Enabled Radiology Performance Platform with Acquisition of CoRead NEW YORK, Nov. 1, 2023 /PRNewswire/ — Covera Health, the leading AI-enabled diagnostic technology company focused on radiology performance measurement and impact, today…
Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease
LONDON–(BUSINESS WIRE)—- $SLN #SenseofSilence–Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced positive topline results from the multiple dose component of the APOLLO phase 1 study of zerlasiran (formerly SLN360) in 36 adults with baseline lipoprotein(a), or Lp(a), levels at or over 150 nmol/L and stable atherosclerotic cardiova
Second Round of Late-Breaking Clinical Trial Results Announced at VIVA23
LAS VEGAS, Oct. 31, 2023 /PRNewswire/ — The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the second of four Late-Breaking Clinical Trial sessions at the…
World’s First Patient Enrolled in SELUTION4DeNovo DEB IDE Trial
MIAMI LAKES, Fla., Oct. 31, 2023 /PRNewswire/ — Cordis has announced enrollment of the first patient in its SELUTION4DeNovo IDE trial, the coronary de novo study for SELUTION SLR™ Drug-Eluting Balloon (DEB), the company’s novel sirolimus-eluting balloon. SELUTION4DeNovo is the first DEB…
Endovascular Engineering, Inc. Announces Positive Initial Results in ENGULF Study for Hēlo™ Thrombectomy System
ENGULF Study utilizing next generation technology in targeting pulmonary embolism MENLO PARK, Calif., Oct. 31, 2023 /PRNewswire/ — Endovascular Engineering (“E2”), a mission driven, venture-backed, medical device company focused on the development and deployment of next generation clot…
Abbott and Stereotaxis Technologies Used in First Integrated Procedures in the United States
ST. LOUIS, Oct. 31, 2023 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the first patients in the United States have been treated successfully utilizing Abbott’s EnSite™ X EP System integrated with Stereotaxis’ Robotic Magnetic Navigation System. […]
Surmodics Announces Launch of Preside™ Medical Device Coating Technology, Providing Industry-Leading Lubricity and Durability to a Broader Range of Complex Device Applications
EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (NASDAQ: SRDX), the global leader in medical device coating technologies, announced the commercial launch of its most advanced hydrophilic medical device coating technology, Preside™ hydrophilic coatings. Preside hydrophilic coatings complement Surmodics’ existing Serene hydrophilic coatings by providing customers with a unique low-friction and low-particulate generation coating to further enhance distal access for neurovascular applications
Toku joins Innovators’ Network at American Heart Association Center for Health Technology & Innovation
SAN DIEGO–(BUSINESS WIRE)–Toku Inc, a provider of an AI-based screening tool for detection of cardiovascular risk through retinal imaging, has joined the American Heart Association Center for Health Technology & Innovation’s (the Center) Innovators’ Network. The Center is focused on building and fostering health technology relationships to develop innovative and scalable solutions. The Innovators’ Network is a health care technology consortium that connects entrepreneurs, providers, resea
Recent
Nyra Medical Receives Prestigious Jon DeHaan Foundation Award for Innovation in Cardiology at EuroPCR 2026
AHN’s Allegheny General Hospital Unveils New, State-of-the-Art Cardiac Cath and Electrophysiology Labs, following Completion of $19 Million Renovation Project
egnite Expands Medical Advisory Board with Three Nationally Recognized Cardiovascular Specialists
Popular
- No commented posts yet